Endocrine Abstracts

In acromegaly, an excessive GH secretion by pituitary adenoma, minimal active disease may be defined as slow progression of characteristic signs and symptoms at presence of slightly elevated or normal IGF1 levels and lack of GH suppression after glucose load. Nadir post-glucose GH level defining active disease is under permanent discussion and depends on assessment methods. IGF1 reference range is wide, must be age-adjusted and often is sex-dependent. From mid-00’s excess...

Introduction: Impaired glucose tolerance and insulin resistance are frequently associated with acromegaly. The aim of this study was to assess the impact of long-acting somatostatin analog treatment on glucose homeostasis in acromegalic patients.Patients and methods: In this prospective study 16 naïve acromegalic patients (eight females, eight males; aged 51.5±10.9 years) were studied before and after 3-month therapy with long-acting somatostat...

Background: Neuroendocrine tumors awareness is developing. Carcinoid syndrome and hormonal overproduction may be controlled with somatostatin analogues in majority of cases. However, due to unspecific symptomatology in early stages of disease, majority of cases are diagnosed when process is disseminated. Co-morbidities and coexisting diseases are present in most of patients. Bone loss may be accelerated by metastizing tumor, peptides secreted or decreased absorption of vitamin...

The aim of the study was to evaluate factors determining bone mineral density (BMD) and serum concentrations of osteocalcin (OC) and carboxyterminal telopeptide of type I collagen (ICTP) in acromegaly. Material consisted of 121 patients with active acromegaly, aged 23–80 years. In the whole group BMD, assessed by DXA, was: 0.35±0.15 at L2–L4, 0.60±0.11 at femoral neck, 0.05±0.12 at Ward’s triangle and 0.59±0.13 at trocha...